Innoviva (INVA) Earnings Date & Reports

Key Takeaways

• Total revenue was $106.1 million for the third quarter of 2026, down 1.6% from $107.8 million a year earlier and below the consensus estimate of roughly $115 million.
• The company reported a GAAP (Generally Accepted Accounting Principles) net loss of $73.9 million, or $1.03 per share, versus net income of $89.9 million, or $1.08 per diluted share, in the prior-year quarter.
• The loss was driven largely by a $139.5 million net unfavorable change in the fair value of equity and long-term investments, primarily tied to a decline in the stock price of Armata Pharmaceuticals.
• U.S. net product sales from the Innoviva Specialty Therapeutics (IST) division reached $43.3 million, up 45% year over year, keeping the company on track toward its 2026 guidance of at least $150 million.
• Income from operations rose 21.9% to $42.2 million, while cash and cash equivalents totaled $581.4 million at quarter end.
• For additional detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper analysis.
• Readers interested in AI-driven trading ideas can explore Trending AI Robots for automated market insights.

Earnings Context and Why It Matters

Innoviva, Inc. (NASDAQ: INVA) is a diversified biopharmaceutical company with three pillars: a durable royalty portfolio tied to respiratory products partnered with Glaxo Group Limited (GSK), a critical care and infectious disease platform called Innoviva Specialty Therapeutics (IST), and a portfolio of strategic healthcare investments. This report matters because it tests whether commercial product growth can offset a maturing royalty stream while the company simultaneously absorbs the volatility of its equity holdings. With the newly launched antibiotic NUZOLVENCE® now commercially available, investors are watching whether IST can sustain its momentum and convert top-line growth into durable operating profitability.

Reported Results

For the third quarter ended September 30, 2026, Innoviva reported total revenue of $106.1 million, a 1.6% decline from $107.8 million in the same period last year and below the consensus estimate of approximately $115 million. Gross royalty revenue from GSK remained stable at $58.1 million, while net product sales rose to $49.4 million, including $43.3 million in U.S. net product sales—a 45% year-over-year increase driven by GIAPREZA®, XACDURO®, and XERAVA®.

On the bottom line, the company posted a GAAP net loss of $73.9 million, or $1.03 per basic and diluted share, compared with net income of $89.9 million, or $1.08 per diluted share, a year ago. This swing was primarily attributable to $139.5 million in net unfavorable changes in the fair value of equity and long-term investments, most notably a decline in the stock price of Armata Pharmaceuticals. Stripping out these non-cash mark-to-market movements, income from operations grew 21.9% to $42.2 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Innoviva, it offers a systematic way to identify comparable opportunities and monitor shifts in sentiment. Consider exploring the AI Screener to streamline your research workflow.

Market Reaction and Investor Sentiment

The market's interpretation of Innoviva's results is likely to hinge on the distinction between its operating performance and its non-cash investment losses. The core commercial business delivered a solid quarter—IST posted 45% U.S. product sales growth and operating income expanded sharply—yet headline results showed a substantial net loss because of fair value markdowns in the healthcare investment portfolio. Investors focused on cash generation and commercial execution may view the writedown as largely non-operational, while those with shorter time horizons could react to the headline EPS miss and the revenue shortfall versus consensus. The stability of the GSK royalty stream and the company's $581.4 million cash position provide a degree of balance-sheet resilience amid that volatility.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important variable is whether Innoviva can sustain IST's commercial trajectory. Management reaffirmed its 2026 target of at least $150 million in U.S. net product sales, and the 45% year-over-year growth in the third quarter suggests the company is on pace. The recent U.S. launch of NUZOLVENCE®, a first-in-class single-dose oral antibiotic for uncomplicated gonorrhea, adds a new revenue lever, though its ramp will depend on establishing market access, distribution, and dispensing infrastructure.

Investors should also monitor the performance of the strategic investment portfolio, which was valued at $535.5 million at quarter end. Because fair value changes in these holdings flow directly through the income statement, swings in the stock price of Armata Pharmaceuticals—the largest position—can materially distort reported earnings in either direction.

Finally, capital allocation remains a focal point. Innoviva repurchased 1.2 million shares for $26.3 million in the quarter under its $125 million buyback program, signaling management's confidence in intrinsic value. Upcoming catalysts include continued XACDURO® adoption following updated 2026 IDSA (Infectious Diseases Society of America) guidance and further evidence on NUZOLVENCE® commercialization, both of which could shape sentiment heading into the fourth-quarter report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations